GN001 Cell Therapy for Lymphoma and Leukemia That Returned or Did Not Respond
Tests GN001, a CAR T cell treatment, in adults with CD19-positive B-cell lymphoma or leukemia.
Plain-language title generated from the registry record
Registry title: GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
Key facts
- Where
- Kunming and Pu'er, ChinaSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07910708, who can take part
Where in China
- The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation ArmyKunming, ChinaTaking people
- Pu'er People's HospitalPu'er, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital
- Trial code
- NCT07910708
- Record updated
- 2 November 2026
- Original description
This study will evaluate GN001 in adults aged 18 to 75 years with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. GN001 is an investigational lentiviral vector-based treatment designed to generate CD19-targeted chimeric antigen receptor (CAR) T cells within the body.Read full original descriptionShow less
An Exploratory Clinical Study of GN001 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
This study will evaluate GN001 in adults aged 18 to 75 years with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. GN001 is an investigational lentiviral vector-based treatment designed to generate CD19-targeted chimeric antigen receptor (CAR) T cells within the body.
The main purpose is to assess safety and tolerability at different doses. The study will also assess antitumor activity, the expansion and persistence of CAR T cells, and biological responses to treatment. Participants will receive GN001 by intravenous infusion. The study includes dose escalation and may include dose expansion after safety review. Long-term safety follow-up is planned.
Inclusion: Aged 18 to 75 years; CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia; Adequate organ function; Signed informed consent.
Exclusion: Any condition that, in the investigator's judgment, makes the participant unsuitable for the study; Pregnant or breastfeeding women.